Oncohema Key

Fig. 9.1 (a) Feedback loops of the PI3K/Akt/mTOR pathway. Red line means inhibition and black activation; in blue: PI3k/Akt/mTOR pathway; in brown: MAPK pathway. (b) Two ways of blocking the…

Fig. 8.1 Chemical structures of sirolimus (a), temsirolimus (b), everolimus (c), and ridaforolimus (d) [4] Rapalogs retain the basic structure of the parent rapamycin compound, but differ by the moiety…

Fig. 12.1 The PI3K pathway and associated inhibitor classes. Schematic representation of the PI3K/Akt/mTOR pathway (red) and the MAPK pathway (blue) including recognized points of crosstalk between the respective cascades….

Fig. 10.1 Oncogenic activation of mTOR may be related to multiple oncogenic activations, mutations of major anti-oncogenes as well as microenvironment-dependent parameters such as hypoxia and nutrient depletion Knowing how…

Fig. 2.1 mTOR signaling pathway (detailed in text) 2.2.1.1 mTORC1 mTORC1 includes two unique binding partners: regulatory associated protein of mTOR (Raptor), which recognizes mTOR substrates through their TOR Signaling…

Clinical characteristic Diagnosis Major features  Facial angiofibromas or forehead plaque Definite TSC: Either 2 major features or 1 major features plus 2 minor features Probable TSC: One major plus 1…

Fig. 1.1 Chemical structure of rapamycin and rapalogs. Rapalogs have the indicated O-substitutions at the C-40 position of rapamycin (red circle) Temsirolimus, formerly known as CCI-779; Torcel®, Wyeth Pharmaceuticals, now…